Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $170
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $125 to $170.
Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $125 to $170.